| Expression pattern: |
DN |
| Associated gene: |
IGF2BP1, PKM2, HNRNPL |
| Associated microRNA: |
- |
| Biological function: |
Inhibits proliferation, inhibits glycolysis and acidic TME, promotes CD8+ T cell activity/infiltration, and enhances anti-PD-1 immunotherapy sensitivity in bladder cancer. |
| Molecular mechanism: |
circFAM13B binds IGF2BP1 (KH3-4 domains) and competitively blocks IGF2BP1 binding to PKM2 3'UTR, reducing PKM2 mRNA stability and inhibiting glycolysis-induced acidic TME; circFAM13B biogenesis is promoted by HNRNPL via back-splicing. |
| Biological pathway or process: |
glycolysis (inhibits); immune regulation (promotes); proliferation (inhibits); ceRNA regulation (other) |
| Detected method: |
Q
S
|
| Validation methods: |
circRNA-seq; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; RT-qPCR; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RNA Pull-Down; Western Blot; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; ELISA; Flow Cytometry（Non-apoptosis/cycle）; IHC (Immunohistochemistry); In Vivo Animal Model; Bioinformatics Analysis; Survival Analysis |
| Clinical significance: |
Low expression in BCa; higher circFAM13B expression is associated with lower tumour stage and better overall survival; proposed biomarker to guide immunotherapy. |
| Description: |
circFAM13B is down-regulated in bladder cancer and acts as a tumor-suppressive circRNA that enhances anti-PD-1 immunotherapy sensitivity. It binds IGF2BP1 to reduce PKM2 mRNA stability, inhibiting glycolysis and the acidic tumor microenvironment, thereby promoting CD8+ T cell function. |
| Confidence score: |
0.8928 |